Acro Biomedical Co., Ltd. is a biotechnology firm focused on developing innovative medical solutions, particularly in regenerative medicine and tissue engineering. The company's competitive position is strengthened by its proprietary technologies in biomaterials, which are utilized in various therapeutic applications across Asia, particularly in Japan and South Korea.
Acro Biomedical generates revenue primarily through the sale of regenerative medicine products, leveraging its proprietary biomaterials technology. The company also engages in R&D collaborations with larger pharmaceutical firms, providing a steady stream of income while maintaining pricing power due to the uniqueness of its products.
Approval of new regenerative medicine products by regulatory bodies
Partnerships with larger pharmaceutical companies for R&D
Market expansion into new geographies, particularly in Asia
Clinical trial results that demonstrate efficacy of products
Regulatory changes impacting approval processes for new therapies
Technological disruption from emerging biotech firms
Increased competition from established biotech companies with greater resources
Potential for rapid advancements in alternative therapies
Negative operating cash flow indicating potential liquidity issues
High ROE paired with negative ROA suggests inefficiencies in asset utilization
moderate - The biotechnology sector is somewhat insulated from economic cycles, but funding for R&D can be affected by broader economic conditions.
Interest rates affect the company's cost of capital for financing R&D projects, potentially impacting growth and valuation multiples.
minimal - The company has a negative debt/equity ratio, indicating a lack of reliance on debt financing.
growth - Investors looking for high-growth opportunities in the biotech sector may find Acro Biomedical appealing due to its innovative product pipeline.
high - The stock has exhibited extreme volatility, particularly with a 3614.3% return over the past year.